This is in continuation to the meetings of the Board of Directors ( Board ) of HealthCare Global Enterprises Limited ( Company ) held on February 17, 2026, approving the offer and issue of equity shares of the Company ( Equity Shares ) on a rights basis to eligible equity shareholders of the Company ( Issue ) and our intimation dated February 24, 2026, regarding the outcome of the meeting of the Board held on February 24, 2026, approving the various terms of the Issue and the meeting of the Board held on February 24, 2026, approving the Letter of Offer.In relation to the aforesaid Issue, opened on March 11, 2026 and closed on March 25, 2026, and pursuant to the finalization of the basis of allotment of the Issue, in consultation with the Kfin Technologies Limited and ( Registrar to the Issue ) and as approved by the designated stock exchange, National Stock Exchange of India Limited, the Rights Issue Committee at its meeting held today, i.e., March 27, 2026, inter alia, considered and approved the allotment of 82,94,566 Equity Shares of Face Value of ₹ 10 each on Rights Basis to the eligible shareholders and/ or renouncee(s) in terms of the Letter of Offer at a price of ₹512 per Equity Share (including a premium of ₹502 per Equity Share) ( Allotment ).
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HealthCare Global Enterprises Limited (HCG) has completed its rights issue and allotted 82,94,566 equity shares at ₹512 per share (face value ₹10, premium ₹502) to eligible shareholders and renouncees. The issue opened on March 11, 2026 and closed on March 25, 2026, with the Rights Issue Committee approving the allotment on March 27, 2026. Total funds raised are approximately ₹424.7 crore. As a result, the company's paid-up equity share capital increased from ₹141.01 crore (14.10 crore shares) to ₹149.30 crore (14.93 crore shares). Kfin Technologies Limited acted as the Registrar, and NSE was the designated stock exchange.
The rights issue has expanded the share base by about 5.9% with shares allotted at a significant premium, diluting existing shareholders only to the extent they did not subscribe. The successful completion signals fresh capital infusion for the oncology hospital chain, though the specific use of proceeds is not disclosed in this filing.